Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Barry Leybovich
Observed name:
Barry C. Leybovich
Institution:
Flatiron Health (United States)
Observed institution:
Flatiron Health (United States)
ORCID:
0009-0006-2438-6843
Observed ORCID:
0009-0006-2438-6843
OpenAlex ID:
A5061395145
Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials
2024
·
Maneet Kaur
, Filip Frahm
, et al.
·
NEJM Evidence
·
31
Clinical characteristics, treatment patterns, and overall survival of real-world patients with idiopathic multicentric Castleman disease.
2021
·
Aaron B. Cohen
, Akshay Swaminathan
, et al.
·
Journal of Clinical Oncology
·
11
Extracting non-small cell lung cancer (NSCLC) diagnosis and diagnosis dates from electronic health record (EHR) text using a deep learning algorithm.
2021
·
Alexander S. Rich
, Barry Leybovich
, et al.
·
Journal of Clinical Oncology
·
4
Trial eligibility criteria (EC) and diversity among patients with advanced non small cell lung cancer (advNSCLC).
2023
·
Maneet Kaur
, Filip Frahm
, et al.
·
Journal of Clinical Oncology
·
2
Accrual of historically underrepresented patients with multiple myeloma using centralized screening in a multicenter study.
2025
·
Anosheh Afghahi
, Daniel P. Sanchez
, et al.
·
Journal of Clinical Oncology
·
1
A multi-modal EHR-based approach to screen patients for oncology clinical trials.
2024
·
Anosheh Afghahi
, Filip Frahm
, et al.
·
JCO Oncology Practice
·
1
PDF
Show more works
View as search
Works count:
6
Citation count:
52
H-index:
3
I10-index:
2
Year
Topic
Type